← Back to signals
JNJ
BUYJohnson & Johnson
Health Care
0.95
PEGY ratio
Rank #163
Why This Matters
This stock appears undervalued relative to its growth and dividend yield. Strong projected growth of 47.4% annually over 5 years. Pays a 2.4% dividend yield.
JNJ trades at 25.9x earnings against 25.0% capped growth (actual 47.4%) + 2.4% yield (PEGY 0.95). Valuation looks favorable — the price is not fully reflecting the growth and yield on offer.
~ Growth estimate uses historical CAGR (forward estimates unavailable)
- • Growth rate derived from historical CAGR — limited analyst coverage.
- • Growth rate capped at 25% for PEGY calculation (actual: 47.4%). Per Peter Lynch methodology, growth above 25% is rarely sustainable over 5 years.
Scan date: 2026-06-02
Valuation
25.9x
P/E Ratio
Growth
47.4%
5yr EPS
Income
2.4%
Div Yield
PEGY Components
PEGY Score0.95
Denominator27.4%
EPS (TTM)$8.63
Market Data
Price$223.51
ExchangeNYSE
S&P 500Dow 30
What Changed
PEGY Score
1.00→0.95(-0.05)
Rank
#177→#163(+14 positions)
vs 7 days ago
Portfolio Context
Founder does not hold this stock.
Not in your portfolio.
Sector: Health Care
PEGY History — 90 days
Data: Yahoo Finance • Updated nightly 11 PM ET • For informational purposes only